I don't think they will take it all the way to market. Partners are good. They help with phase 3 trial design, they bring upfront cash to the table and they help to diversify risk because YM can focus cash and human resources on developing the pipeline. Going it alone can payoff big but it can also backfire. I think this comes down to risk/reward. My YE price target is $5ish unless we get bought but we're at $2 and you don't often see 150% buyout premiums. I think we're best off with a nice licensing deal. Most likely in my book: Amgen, J&J, BMS, Pfizer (especially with their RA JAK looking good) and Celgene. Celgene went all the way of course but they also had revenues. It's a tough call here. I'm sure partners are circling. The data looks too good and JAKs are attractive right now. Thank Galapagos for that awesome deal they did. It's a great comp. That type of deal brings YM to the $4-5 level.